Dexmedetomidine alleviatesmyocardial ischemia-reperfusion injury in rat models

doi:10.16352/j.issn.1001-6325.2025.03.0303

Abstract

Abstract: Objective To investigate the relationship between the protective mechanism of dexmedetomidine (Dex) against myocardial ischemia-reperfusion(I/R) injury and cuproptosis. Methods The Langendorff models were constructed using SD rats(I/R group), which were divided into 4 groups according to different interventions during reperfusion as: sham group, I/R group, Dex group and Dex+ES-Cu group. The left ventricular peak pressure(LVSP)of the rats in the above four groups were continuously monitored in the immediate pre-ischemic period(T0), 30 min of reperfusion(T1), 60 min reperfusion(T2), 90 min reperfusion(T3),2 h of reperfusion(T4). Left ventricular end-diastolic pressure(LVEDP), heart rate (HR), maximum rate of rise of left ventricular pressure (+dp/dtmax) and maximum rate of drop. Subsequently, the extent of myocardial infarction was shown by1% triphenyltetrazoliumchloride (TTC) staining, and the degree of myocardial fibrosis was assessed by Sirius red staining; Myocardial enzyme profiles, oxidative stress and inflammation indexes were detected by ELISA; Copper ions were detected by copper ion detection kit in myocardial tissues; ATF3, SPI1 and FDX1 protein level expression was detected by Western blot. Results Compared with the sham-operated group, the extent of myocardial infarction and fibrosis increased in the I/R group(P＜0.05), the level of serum MDA, IL-6, IL-1β, and TNF-α was elevated(P＜0.05), and the activity of SOD and GSH-Px decreased(P＜0.05). The Dex group significantly alleviated the above changes in the I/R group, and compared with the Dex group, in the Dex+ES-Cu group myocardial tissue copper ion content at the end of perfusion was increased(P＜0.05). Both ATF3 and SPI1 protein were increased and FDX1 protein was decreased(P＜0.05). Conclusions Dex can regulate copper metabolism and improve myocardial ischemia-reperfusion injury(MI/RI) resulted from oxidative stress and inflammation in rat model.

Key words: dexmedetomidine, cuproptosis, myocardial ischemia-reperfusion injury(MI/RI), oxidative stress, inflammation

CLC Number:

R310.99

LIU Genfeng, NAN Lu, GAO Qin, CHEN Yixuan, ZHANG Jing, YU Peng, YU Shuchun. Dexmedetomidine alleviatesmyocardial ischemia-reperfusion injury in rat models[J]. Basic & Clinical Medicine, 2025, 45(3): 303-309.

References

[1] Zhao B, Li D, Zhang S, et al. Dexmedetomidine attenuates cerebral ischemia-reperfusion injury in rats by inhibiting the JNK pathway[J]. Ann Palliat Med, 2021, 10: 6768-6778.
[2] Cong D, Yu Y, Meng Y, et al. Dexmedetomidine (Dex) exerts protective effects on rat neuronal cells injured by cerebral ischemia/reperfusion via regulating the Sphk1/S1P signaling pathway[J]. J Stroke Cerebrovasc Dis, 2023, 32: 106896.doi:10.1016/j.jstrokecerebrovasdis.2022.106896.
[3] Hu B, Tian T, Li XT, et al. Dexmedetomidine postconditioning attenuates myocardial ischemia/reperfusion injury by activating the Nrf2/Sirt3/SOD2 signaling pathway in the rats[J]. Redox Re, 2023, 28: 2158526.doi:10.1080/13510002.2022.2158526.
[4] Chen ZR, Hong Y, Wen SH, et al. Dexmedetomidine pretreatment protects against myocardial ischemia/reperfusion injury by activating STAT3 signaling[J]. Anesth Analg, 2023, 137: 426-439.
[5] 戴小燕. Langendorff离体心脏灌注模型的制备及应用[J]. 医学综述, 2012, 18: 2036-2039.
[6] Yuan M, Meng XW, Ma J, et al. Dexmedetomidine protects H9c2 cardiomyocytes against oxygen-glucose deprivation/reoxygenation-induced intracellular calcium overload and apoptosis through regulating FKBP12.6/RyR2 signaling[J]. Drug Des Devel Ther, 2019, 13: 3137-3149.
[7] Huo S, Wang Q, Shi W, et al. ATF3/SPI1/SLC31A1 signaling promotes cuproptosis induced by advanced glycosylation end products in diabetic myocardial injury[J]. Int J Mol Sci, 2023, 24: 1667.doi:10.3390/ijms24021667.
[8] Xiao Y, Li J, Qiu L, et al. Dexmedetomidine protects human cardiomyocytes against ischemia-reperfusion injury through α2-adrenergic receptor/AMPK-dependent autophagy[J]. Front Pharmacol, 2021, 12: 615424.doi:10.3389/fphar.2021.615424.
[9] 张晓青, 徐雪. 右美托咪啶器官保护作用的研究进展[J]. 基础医学与临床,2012, 32: 844-846.
[10] Tang Y, Jia C, He J, et al. The application and analytical pathway of dexmedetomidine in ischemia/reperfusion injury[J]. J Anal Methods Chem, 2019, 2019: 7158142.doi:10.1155/2019/7158142.
[11] Sun M, Wang R, Xia R, et al. Amelioration of myocardial ischemia/reperfusion injury in diabetes: a narrative review of the mechanisms and clinical applications of dexmedetomidine[J]. Front Pharmacol, 2022, 13: 949754.doi:10.1155/2019/7158142.
[12] Yang K, Ma Y, Xie C, et al. Dexmedetomidine combined with propofol attenuates myocardial ischemia/reperfusion injury by activating the AMPK signaling pathway[J]. Heliyon, 2023, 9: e22054.doi:10.1016/j.heliyon.2023.e22054.
[13] Zhang T, Mei Q, Dai S, et al. Use of dexmedetomidine in patients with sepsis: a systematic review and meta-analysis of randomized-controlled trials[J]. Ann Intensive Care, 2022, 12: 81.doi:10.1186/s13613-022-01052-2.
[14] Tao WH, Shan XS, Zhang JX, et al. Dexmedetomidine attenuates ferroptosis-mediated renal ischemia/reperfusion injury and inflammation by inhibiting ACSL4 via α2-AR[J]. Front Pharmacol, 2022, 13: 782466.doi:10.3389/fphar.2022.782466.
[15] Guo Q, Ma M, Yu H, et al. Dexmedetomidine enables copper homeostasis in cerebral ischemia/reperfusion via ferredoxin 1[J]. Ann Med, 2023, 55: 2209735.doi:10.1080/07853890.2023.2209735.